OrbiMed has closed its OrbiMed Private Investments V with just over $735 million, including $36 million from the GP. Fund V will invest in all stages and sectors of the healthcare industry, with a focus on biopharmaceutical, medical device and diagnostics companies in North American and Europe.
OrbiMed, a leading investment firm focused on the healthcare sector, today announced the closing of its next venture capital fund, OrbiMed Private Investments V, LP, with just over $735 million in commitments, including approximately $36 million from the General Partner. Investors in the fund include some of the largest endowments, foundations, sovereign wealth funds and financial institutions globally.
“We are seeking novel healthcare innovations across biopharma, devices, diagnostics and healthcare I.T. at any stage of development”
Consistent with its predecessor funds, the new fund will invest in all stages and sectors of the healthcare industry, with a focus on biopharmaceutical, medical device, and diagnostics companies located in North America and Europe. The new fund is expected to invest in approximately 30 portfolio companies in amounts generally ranging from $10 million to $50 million.
Carl Gordon, a Partner at OrbiMed and Co-Head of Global Private Equity, noted, “This is an exciting time to launch our next fund, given the combination of the high rate of new FDA drug approvals, a vibrant IPO window, and the accelerating level of innovation from companies across the life sciences investment universe.”
“We are seeking novel healthcare innovations across biopharma, devices, diagnostics and healthcare I.T. at any stage of development,” commented Jonathan Silverstein, also an OrbiMed Partner and Co-Head of Global Private Equity. “This new fund will leverage OrbiMed’s entire global platform, which now includes more than 80 employees globally investing over $8 billion across healthcare public equities, private equities, royalties and credit opportunities.”
OrbiMed is a leading investment firm dedicated exclusively to the healthcare sector, with over $8 billion in assets under management. OrbiMed invests globally across the spectrum of healthcare companies, from venture capital start-ups to large multinational companies. OrbiMed’s team of more than 80 employees manages a series of private equity funds, public equity funds, royalty/debt funds and other investment vehicles. OrbiMed maintains its headquarters in New York City, with additional offices in San Francisco, Shanghai, Mumbai and Herzliya.
As one of the largest investment firms dedicated to the healthcare sector, OrbiMed seeks to be a capital provider of choice, bringing the global resources required to be an exceptional long-term partner for building world-class healthcare companies. www.OrbiMed.com.